Pembrolizumab‐axitinib‐induced tumor lysis syndrome in a patient with metastatic renal cancer

Tumor lysis syndrome is uncommon in solid tumors but with the use of immunotherapy (checkpoint inhibitors) their incidence is increasing. Physicians need to take adequate precautions while treating patients with immunotherapy. The findings of our case report will help improve our current understandi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Manan, Jain, Sanjay, Abe, Temidayo, Surapaneni, Phani Keerthi, Bhatia, Kapil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141709/
https://www.ncbi.nlm.nih.gov/pubmed/32274041
http://dx.doi.org/10.1002/ccr3.2737
_version_ 1783519248829644800
author Shah, Manan
Jain, Sanjay
Abe, Temidayo
Surapaneni, Phani Keerthi
Bhatia, Kapil
author_facet Shah, Manan
Jain, Sanjay
Abe, Temidayo
Surapaneni, Phani Keerthi
Bhatia, Kapil
author_sort Shah, Manan
collection PubMed
description Tumor lysis syndrome is uncommon in solid tumors but with the use of immunotherapy (checkpoint inhibitors) their incidence is increasing. Physicians need to take adequate precautions while treating patients with immunotherapy. The findings of our case report will help improve our current understanding of tumor lysis syndrome specially in solid tumors and will help in developing multidisciplinary treatment and prophylaxis strategies for this uncommon, but potentially fatal complication.
format Online
Article
Text
id pubmed-7141709
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71417092020-04-09 Pembrolizumab‐axitinib‐induced tumor lysis syndrome in a patient with metastatic renal cancer Shah, Manan Jain, Sanjay Abe, Temidayo Surapaneni, Phani Keerthi Bhatia, Kapil Clin Case Rep Case Reports Tumor lysis syndrome is uncommon in solid tumors but with the use of immunotherapy (checkpoint inhibitors) their incidence is increasing. Physicians need to take adequate precautions while treating patients with immunotherapy. The findings of our case report will help improve our current understanding of tumor lysis syndrome specially in solid tumors and will help in developing multidisciplinary treatment and prophylaxis strategies for this uncommon, but potentially fatal complication. John Wiley and Sons Inc. 2020-02-15 /pmc/articles/PMC7141709/ /pubmed/32274041 http://dx.doi.org/10.1002/ccr3.2737 Text en © 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Shah, Manan
Jain, Sanjay
Abe, Temidayo
Surapaneni, Phani Keerthi
Bhatia, Kapil
Pembrolizumab‐axitinib‐induced tumor lysis syndrome in a patient with metastatic renal cancer
title Pembrolizumab‐axitinib‐induced tumor lysis syndrome in a patient with metastatic renal cancer
title_full Pembrolizumab‐axitinib‐induced tumor lysis syndrome in a patient with metastatic renal cancer
title_fullStr Pembrolizumab‐axitinib‐induced tumor lysis syndrome in a patient with metastatic renal cancer
title_full_unstemmed Pembrolizumab‐axitinib‐induced tumor lysis syndrome in a patient with metastatic renal cancer
title_short Pembrolizumab‐axitinib‐induced tumor lysis syndrome in a patient with metastatic renal cancer
title_sort pembrolizumab‐axitinib‐induced tumor lysis syndrome in a patient with metastatic renal cancer
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141709/
https://www.ncbi.nlm.nih.gov/pubmed/32274041
http://dx.doi.org/10.1002/ccr3.2737
work_keys_str_mv AT shahmanan pembrolizumabaxitinibinducedtumorlysissyndromeinapatientwithmetastaticrenalcancer
AT jainsanjay pembrolizumabaxitinibinducedtumorlysissyndromeinapatientwithmetastaticrenalcancer
AT abetemidayo pembrolizumabaxitinibinducedtumorlysissyndromeinapatientwithmetastaticrenalcancer
AT surapaneniphanikeerthi pembrolizumabaxitinibinducedtumorlysissyndromeinapatientwithmetastaticrenalcancer
AT bhatiakapil pembrolizumabaxitinibinducedtumorlysissyndromeinapatientwithmetastaticrenalcancer

Ejemplares similares